DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model

Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2010-04, Vol.31 (8), p.926-935
Main Authors: Wordsworth, Sarah, Leal, José, Blair, Edward, Legood, Rosa, Thomson, Kate, Seller, Anneke, Taylor, Jenny, Watkins, Hugh
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biological and medical sciences
Cardiology. Vascular system
Cardiomyopathy, Hypertrophic, Familial - diagnosis
Cardiomyopathy, Hypertrophic, Familial - economics
Cardiomyopathy, Hypertrophic, Familial - genetics
Child
Cost-Benefit Analysis
Cost-effectiveness analysis
Death, Sudden, Cardiac - prevention & control
Decision Trees
Forecasting
Genetic Testing - economics
Genetic Testing - standards
Genetics
Heart
Humans
Hypertrophic cardiomyopathy
Medical sciences
Middle Aged
Models, Economic
Myocarditis. Cardiomyopathies
Pedigree
Risk Assessment
Sensitivity and Specificity
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was €14 397 for the cascade genetic compared with the cascade clinical approach. Genetic diagnostic strategies are more likely to be cost-effective than clinical tests alone. The costs for cascade molecular genetic testing were slightly higher than clinical testing in the short run, but this was largely because the genetic approach is more effective and identifies more individuals at risk. Conclusion The use of molecular genetic information in the diagnosis and management of HCM is a cost-effective approach to the primary prevention of SCD in these patients.
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehq067